

Imkeldi (imatinib) - New drug approval

- On November 22, 2024, the FDA approved Shorla Oncology's Imkeldi (imatinib) oral solution.
- Imatinib is available as an oral tablet under the brand name Gleevec® and its generic alternatives.
- The indications for Imkeldi mirror those of Gleevec (10 approved indications). Refer to the Imkeldi drug label for a complete list of the indications for use.
- Warnings and precautions for Imkeldi include fluid retention and edema; hematologic toxicity; congestive heart failure and left ventricular dysfunction; hepatotoxicity; hemorrhage; gastrointestinal disorders; hypereosinophilic cardiac toxicity; dermatologic toxicities; hypothyroidism; embryo-fetal toxicity; growth retardation in children and adolescents; tumor lysis syndrome; impairments related to driving and using machinery; renal toxicity; and measuring device.
- The most common adverse reactions (≥ 30%) with Imkeldi use were edema, nausea, vomiting, muscle cramps, musculoskeletal pain, diarrhea, rash, fatigue, and abdominal pain.
- Refer to the Imkeldi drug label for complete dosing and administration recommendations across its various indications.
- Sharla Oncology's launch plans for Imkeldi are pending. Imkeldi will be available as a 80 mg/mL oral solution.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.